CD19.20.22 CAR T cells therapy (University Of Maryland, Baltimore)

N/A

Report date: 2025/09/15 20:01:49

Base Information

Drug NameCD19.20.22 CAR T cells therapy (University Of Maryland, Baltimore)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT lymphocyte replacementsB-lymphocyte antigen CD19 modulatorsB-lymphocyte antigen CD20 modulators
TargetsB-lymphocyte antigen CD19B-lymphocyte antigen CD20
Therapy Area/IndicationsPrimary mediastinal B cell lymphomaRichter's SyndromeLymphoma, Mantle-Cell +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesUniversity Of Maryland, Baltimore
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of Maryland, Baltimore
Inactive CompaniesN/A
Active IndicationsPrimary mediastinal B cell lymphomaRichter's SyndromeLymphoma, Mantle-Cell +[8] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A